Research programme: metabolic disease therapeutics - Blue Therapeutics
Latest Information Update: 16 Sep 2021
At a glance
- Originator Blue Therapeutics
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 24 Aug 2021 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route) (Blue therapeutics pipeline, August 2021)
- 06 May 2021 Preclinical trials in Diabetes mellitus in USA (unspecified route) (Blue Therapeutics pipeline, May 2021).